Sichuan Kelun Pharmaceutical Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Sichuan Liu
Chief executive officer
CN¥4.8m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 15.9yrs |
| CEO ownership | 0.5% |
| Management average tenure | 9.3yrs |
| Board average tenure | 6.1yrs |
Recent management updates
Recent updates
An Intrinsic Calculation For Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Suggests It's 37% Undervalued
Mar 11
Here's Why We Think Sichuan Kelun Pharmaceutical (SZSE:002422) Is Well Worth Watching
Feb 24We Think Sichuan Kelun Pharmaceutical (SZSE:002422) Can Manage Its Debt With Ease
Feb 07Why Investors Shouldn't Be Surprised By Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E
Dec 23Here's Why Sichuan Kelun Pharmaceutical (SZSE:002422) Has Caught The Eye Of Investors
Nov 17Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet
Oct 28Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E No Reason For Excitement
Sep 22Should You Be Adding Sichuan Kelun Pharmaceutical (SZSE:002422) To Your Watchlist Today?
Aug 16Is Sichuan Kelun Pharmaceutical (SZSE:002422) Using Too Much Debt?
Jul 12Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Prospects Need A Boost To Lift Shares
Jun 11An Intrinsic Calculation For Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Suggests It's 45% Undervalued
May 21CEO
Sichuan Liu (40 yo)
15.9yrs
Tenure
CN¥4,800,000
Compensation
Mr. Sichuan Liu has been a Director of Sichuan Kelun Pharmaceutical Co., Ltd. since June 26, 2009 and serves as its General Manager. He is a Non-Executive Director of Sichuan Kelun-Biotech Biopharmaceutica...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | no data | CN¥4.80m | 0.52% CN¥ 282.9m | |
| CFO & Deputy GM | 10.6yrs | CN¥3.00m | 0.028% CN¥ 15.1m | |
| Deputy General Manager | 9.3yrs | CN¥2.89m | 0.010% CN¥ 5.6m | |
| Deputy General Manager | 3.1yrs | CN¥3.10m | 0.0094% CN¥ 5.1m | |
| Deputy GM & Director | no data | CN¥134.60k | 0.019% CN¥ 10.0m | |
| Deputy GM & Secretary of the Board of Directors | 14.1yrs | CN¥3.00m | 0.027% CN¥ 14.6m | |
| Officer | no data | CN¥700.00k | no data | |
| Deputy General Manager | 11.9yrs | CN¥3.00m | 0.017% CN¥ 9.0m | |
| Deputy General Manager | 10.3yrs | CN¥3.00m | 0.011% CN¥ 6.1m | |
| Deputy General Manager | 5.1yrs | CN¥2.40m | no data | |
| Deputy General Manager | 3.1yrs | CN¥1.65m | 0.0076% CN¥ 4.1m | |
| Deputy General Manager | 3.1yrs | CN¥900.00k | 0.0031% CN¥ 1.7m |
9.3yrs
Average Tenure
48yo
Average Age
Experienced Management: 002422's management team is seasoned and experienced (9.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 15.9yrs | CN¥4.80m | 0.52% CN¥ 282.9m | |
| Deputy GM & Director | less than a year | CN¥134.60k | 0.019% CN¥ 10.0m | |
| Chairman of the Board of Directors | no data | CN¥2.00m | 23.83% CN¥ 12.8b | |
| Non Independent Director | 6.1yrs | CN¥100.00k | no data | |
| Employee-Representative Member of the Board of Supervisors | 17yrs | no data | 0.0044% CN¥ 2.4m | |
| Member of the Board of Supervisors | 9.3yrs | no data | no data | |
| Independent Director | 3.9yrs | CN¥100.00k | no data | |
| Non Independent Director | 11yrs | CN¥100.00k | no data | |
| Director | less than a year | no data | no data | |
| Chairman of Board of Supervisors | 10.2yrs | no data | 0.00063% CN¥ 339.6k | |
| Independent Director | 3.9yrs | CN¥100.00k | no data | |
| Director | less than a year | no data | no data |
6.1yrs
Average Tenure
55yo
Average Age
Experienced Board: 002422's board of directors are considered experienced (6.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/15 09:40 |
| End of Day Share Price | 2025/05/15 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sichuan Kelun Pharmaceutical Co., Ltd. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Jin Zhang | China International Capital Corporation Limited |
| Yinhao Tang | Citic Securities Co., Ltd. |